466 results about "Bone resorption" patented technology

A system and method includes surgical instrumentation, implants, bone graft material, and measurement equipment to enable a spine fusion procedure to proceed more accurately, efficiently and safely by allowing precision measurement of the characteristics of the intervertebral space, selection of and provision of new implants, placement of an intervertebral implant, and to help overcome bone resorption all where improved healing thereafter takes place.

Disclosed is a composition of matter of the formula

(X¹)_a—(F¹)_d—(X²)_b—(F²)_e—(X³)_c  (I)

and multimers thereof, in which F¹ and F² are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X¹, X², and X³ are each independently -(L)_f-P-(L)_g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.

Disclosed are compositions and methods for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin D₃ suitable for once-weekly dosing. Compositions and methods of the invention provide vitamin D nutrition during bisphosphonate treatment to facilitate normal bone formation and mineralization while minimizing the occurrence of or potential for the complications associated with vitamin D insufficiency, such as hypocalcaemia and osteomalacia. Also disclosed are methods for manufacturing compositions of the present invention, for measuring stability and degradation of those compositions, and for measuring blood plasma levels of vitamin D.

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens.

The present invention provides novel biomaterials comprising one or more of Mg, Zn and F ions in a carbonate-containing biphasic calcium phosphate (BCP) system. The biomaterial may contain Mg, Zn, F, Mg and Zn, Mg and F, Zn and F, or Mg, Zn and F. The biomaterial may be substantially similar in composition to bone mineral (a carbonate apatite). The biomaterial may feature slow release of Mg, Zn, F, Ca, and P ions. The biphasic calcium phosphate, BCP, may be a mixture of unsubstituted hydroxyapatite (HA) and unsubstituted .-TCP, Ca₃(PO₄)₂. BCP of varying HA/.-TCP ratios may be produced by sintering calcium-deficient apatite, for instance having a Ca/P<1.5, 1.6, 1.67, 1.75 or 1.8 that has been prepared either by a precipitation or by a hydrolysis method or by a solid-state reaction. The amount of each component (by weight %) present in the biomaterials may be as follows: Mg 0.5 to 12 wt %, Zn 1 to 12 wt %, F 0.1 to 4 wt %, calcium 20 to 40 wt %, phosphate 10 to 20 wt %, and carbonate (CO₃) 1 to 20 wt %. The biomaterial may further comprise one or more other ion such as strontium, manganese, copper, boron or silicate, or one or more other organic moiety such as a protein, a peptide, or a nutraceutical which may provide antioxidant, anti-bacterial or anti-inflammatory properties. The invention also provides methods of inhibiting bone resorption, methods of treating osteoporosis or delaying the onset of osteoporosis, methods of treating a bone fracture, and methods of inhibiting osteoclast activity. Further, the invention provides methods of treating or reversing bone deficiencies such as bone loss, similar to osteoporosis, caused all or in part by a mineral deficient diet, a disease such as cancer or osteopenia, a treatment such as steroid therapy or radiation therapy, or a physical condition such as immobilization.

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

The invention discloses an injectable composite bone cement of hydroxyapatite-PMMA containing strontium, consisting of a powder and a liquid monomer with the weight ratio of 1.5 to 2.5:1, wherein the main components of the powder are 10 to 30% of hydroxyapatite containing strontium and 70 to 90% of PMMA and/or PMMA/styrene copolymer in percentage by weight, and the main components of the liquid monomer are 98 to 99.9% of MMA and 0.1 to 2% of DMPT in percentage by weight. The bone cement has the advantages of safety, no toxity, convenient operation and molding, and low polymerization temperature. The bone cement has good biomechanics intensity, biological activity and biocompatibility, and can promote the growth of the bone, suppress the bone resorption and be used in radiological imaging because of containing the metallic element of strontium.

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

The present invention pertains to cannabinoid (CB) receptor inverse agonists and neutral antagonists, and especially CB1 and CB2 inverse agonists and neutral antagonists; such as, for example, certain pyrazole compounds; their use in the inhibition of osteoclasts (for example, the inhibition of the survival, formation, and/or activity of osteoclasts), and/or in the inhibition of bone resorption; their use in connection with treatment of bone disorders, such as conditions mediated by osteoclasts (e.g., increased osteoclast activity) and/or characterised by (e.g., increased) bone resorption, such as osteoporosis (e.g., osteoporosis not associated with inflammation; e.g., osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer associated bone disease, and Paget's disease of bone.

A prosthetic implant having a fixation stem with varying stiffness is disclosed. The stem comprises an elongated core and segments extending outward from the core. The segments are spaced apart so as to define transverse grooves surrounding the core between adjacent segments. The longitudinal length of the grooves, and the materials used for the core and the segments are selected such that the stiffness of the stem varies from the proximal end to the distal end. Typically, the stiffness of the stem will be lower at the distal end such that the distal end of the stem bears less force when loaded and thereby transfers more load to the proximal end of the stem, which has a higher stiffness. As a result, stress shielding, in which the load bypasses the proximal end of the stem, is minimized and bone resorption adjacent the proximal end of the stem is decreased.

The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A_2A receptor, in particular, an agonist of an adenosine A_2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A_2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A_2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.

The present invention relates to the surprising discovery that the combination of several agents, each well known for its established role in treating cancer, inflammation, hemostasis, bone resorption or serving as a solubilizing vehicle, results in a synergistic anti-cancer composition. Furthermore, the combination of at least three agents allows the cytotoxic agent, such as cyclophosphamide, to be used at a lower dosage than when administered alone. One predicted consequence of this treatment, therefore, is a highly desirable reduction in toxic side effects due to the cytotoxic agent.

The invention relates to a hollow short implant of a dental implant, which comprises an one-stage structure and a two-stage structure, wherein the one-stage implant part is connected with an abutment part into a whole; the two-stage structure comprises an implant, a bridge adapter ring and a central bolt; peripheral cylinder spirochaeta of the implant part is divided into three stages, saw-tooth double thread in the main part of the implant can bear heavier load; the hollow structural design of the implant part keeps live bone column with a base and blood supply so as to enhance the supporting strength of the bone and the implant; a self-tapping socket can make bone tissue of the internal and external of the implant grow through and heal; a platform transfer design allows the epithelial cuff of the gum around the implant more reliable to avoid bone resorption caused by micro moving and micro leakage. The short hollow implant realizes combination of the internal and external bone, increases the combination area and supporting strength for a short or a long term, can be implanted rapidly with high strength, better retention in the early stage, high success rate in a long term, and solves the problem that the upper and lower jaws abrase the dental area in the conventional oral implant technology.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing electricity are provided for non-human animals. Electrodes are used to deliver an electrical current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens.

The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase the bone mass and bone strength by controlling the whole bone metabolism. The pharmaceutical composition or combination product of the invention comprising a non-living body-derived non-peptide osteoblast differentiation promoting compound and a bisphosphonate having a bone resorption inhibitory action is useful as a bone mass increasing inducer which can increase the bone mass and/or bone strength by controlling the bone metabolism.

Intramedullary medical devices (e.g., intramedullary nails) and methods for their use and manufacture are described herein. The intramedullary medical devices described herein may provide sustained compressive forces across a bone fusion site despite bone resorption processes. Through various embodiments, the intramedullary medical devices described herein may provide non-linear force curves relative to displacement. Intramedullary medical devices are described with multiple elements made of different materials. Examples of intramedullary medical devices are described with shape memory alloys.